Biomarkers (1)
A65 – A103
- A65: Early Detection of oral cancer by pulsed laser photoacoustic spectroscopy: a pilot study
- A66: Molecular imaging without stains using Raman spectroscopy, a potential histopathological tool
- A67: Progression of Barrett’s oesophagus maybe driven by gastrin and the CCK-2 receptor in a hypergastrinemic environment
- A68: Increased CpG island methylation during cisplatin selection of ovarian cancer cells
- A69: BCR-ABL mutation a tool for imatinib resistance in chronic myeloid leukemia patients
- A70: Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple negative immunophenotype
- A71: Abstract withdrawn
- A72: Cancer-induced bone pain: objective functional assessment in relation to palliative radiotherapy
- A73: Cheaper, faster, more powerful imaging-based clinical trials
- A74: Methylation profiling identifies over-representation of aberrant methylation of transcriptional activators in chemoresistant ovarian cancer cell lines
- A75: The molecular basis of the chemosensitivity of uveal melanoma to treosulfan and gemcitabine
- A76: Biomarkers of response to therapy in gastric/gastro-oesophageal adenocarcinoma
- A77: Trial designs to assess biomarkers in clinical practice
- A78: Biomarker analysis of gene-modified T-cells for a CR-UK Phase 1 clinical trial: development and validation of protocols for use in a clinical setting
- A79: Aberrant promoter hypermethylation of DAPK gene is an independent prognostic factor in patients with diffuse large B-cell lymphomas
- A80: The role of c-FLIP in mediating chemoresistance in acute myeloid leukaemia and potential prognostic significance
- A81: Use of a dedicated microarray platform for biomarker discovery from formalin fixed and paraffin embedded tissue
- A82: Clinical utility of circulating markers of epithelial cell death in pancreatic cancer
- A83: Eukaryotic translation initiation factor 4E and angiogenesis in human astrocytomas
- A84: Application of iTRAQ and LC-MS-MS for the discovery of differentially expressed pancreatic ductal adenocarcinoma proteins using serum and pancreatic juice
- A85: Prognostic significance of cleaved PARP in gastro-oesophageal cancer
- A86: Computed tomography overestimates oesophageal tumour length particularly after neoadjuvant chemotherapy: implications for radiotherapy planning
- A87: Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 AND VEGF in familial and sporadic renal cell carcinoma
- A88: Role of human epidermal receptor targeted therapies in chemo-sensitization of oesophageal adenocarcinoma cells
- A89: Is there are a role for immunotherapy in platinum sensitive and resistant ovarian cancer patients?
- A90: Proteomic profiling of patients with cholangiocarcinoma to identify plasma biomarkers
- A91: Can plasma proteomic profiles predict response to chemotherapy in an oesophageal cancer xenograft model?
- A92: The utility of serological cell death biomarkers to guide development of new therapeutics
- A93: Validation of multicolour flow cytometry assays of apoptosis for clinical trial use
- A94: ADAM-17 and TGF-α are key regulators of chemotherapy-induced EGFR activation
- A95: Radiation induction of p53 in vivo in normal human breast tissues
- A96: Development of novel pharmacodynamic biomarkers of PI3-kinase inhibition using gene expression microarrays
- A97: CD69 as a novel biomarker for histone deacetylase inhibitors
- A98: Combining molecular diagnostics to identify patients with head and neck squamous cell carcinoma at risk of developing local recurrence
- A99: Prognostic significance of periodic acid-schiff-positive patterns in kidney cancer
- A100: STAT signalling: a potential therapeutic target in bladder cancer?
- A101: mRNA expression analysis of all 33 tetraspanin family members in malignant and normal human oral squamous cell lines
- A102: Osteopontin-c is a selective marker of breast cancer
- A103: Quantitative pyrosequencing methylation assay (PMA): correlation with gene expression in head and neck cancer
